Department of Cell and Developmental Biology
While decades of research have identified molecular pathways inducing and promoting stages of prostate cancer malignancy, studies addressing dynamic changes of cancer-related regulatory factors in a prostate tumor progression model are limited. Using the TRAMP mouse model of human prostate cancer, we address mechanisms of deregulation for the cancer-associated transcription factors, Runx1 and Runx2 by identifying microRNAs with reciprocal expression changes at six time points during 33 weeks of tumorigenesis. We molecularly define transition stages from PIN lesions to hyperplasia/neoplasia and progression to adenocarcinoma by temporal changes in expression of human prostate cancer markers, including the androgen receptor and tumor suppressors, Nkx3.1 and PTEN. Concomitant activation of PTEN, AR, and Runx factors occurs at early stages. At late stages, PTEN and AR are downregulated, while Runx1 and Runx2 remain elevated. Loss of Runx-targeting microRNAs, miR-23b-5p, miR-139-5p, miR-205-5p, miR-221-3p, miR-375-3p, miR-382-5p, and miR-384-5p, contribute to aberrant Runx expression in prostate tumors. Our studies reveal a Runx/miRNA interaction axis centered on PTEN-PI3K-AKT signaling. This regulatory network translates to mechanistic understanding of prostate tumorigenesis that can be developed for diagnosis and directed therapy.
Rights and Permissions
Citation: Oncotarget. 2016 Oct 25;7(43):70462-70474. doi: 10.18632/oncotarget.11992. Link to article on publisher's site. All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
DOI of Published Version
AR, PTEN, TRAMP, miRNA targeting Runx, prostate cancer progression
Farina, Nicholas H.; Zingiryan, Areg; Akech, Jacqueline; Callahan, Cody J.; Lu, Huimin; Stein, Janet L.; Languino, Lucia R.; Stein, Gary S.; and Lian, Jane B., "A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice" (2016). Open Access Articles. 2971.
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.